![(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]t…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fcas-image%2Fthumb-webp%2F402219-ticagrelor.webp&w=3840&q=75)
CAS 274693-27-5
:(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
Description:
The chemical substance with the name "(1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol" and CAS number "274693-27-5" is a complex organic compound characterized by its multi-cyclic structure and various functional groups. It features a cyclopentane core with multiple stereocenters, indicating chirality, which can influence its biological activity and interactions. The presence of a triazolopyrimidine moiety suggests potential pharmacological properties, as this scaffold is often associated with various therapeutic effects. Additionally, the difluorophenyl and propylsulfanyl groups may enhance lipophilicity and modulate the compound's binding affinity to biological targets. The hydroxyl groups contribute to its polarity and solubility in aqueous environments, which can affect its bioavailability. Overall, this compound's intricate structure and functional diversity suggest potential applications in medicinal chemistry, particularly in the development of novel therapeutics.
Formula:C23H28F2N6O4S
InChI:InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1
InChI key:InChIKey=OEKWJQXRCDYSHL-FNOIDJSQSA-N
SMILES:N(C1=C2C(N(N=N2)[C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)=NC(SCCC)=N1)[C@H]4[C@@H](C4)C5=CC(F)=C(F)C=C5
Synonyms:- (1S,2S,3R,5S)-3-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
- (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
- 1,2-Cyclopentanediol, 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-, (1S,2S,3R,5S)-
- Ar-C 126532Xx
- Ar-C126532
- Azd 6140
- Azd6140
- Brilinta
- Brilique
- Possia
- Ticagrelor
- Triafluocyl
- (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
- Ticagrelor(AR-C 126532XX
- Unii-glh0314rvc
- (1S,2S,3R,5S)-3-(7-(((1S,2S)-2-(3,4-difluorophenyl)cyclopropyl)aMino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
- Tecagrelor
- 3-[7-[[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]aMino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)-,(1S,2S,3R,5S)-
- Ticagrelor (AZD6140)
- (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylaMino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyriMidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
- Ticarelor
- Ticargrelor
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 16 products.
Ticagrelor
CAS:Drugs containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structureFormula:C23H28F2N6O4SColor and Shape:White Off-White Pink PowderMolecular weight:522.18608(1S,2S,3R,5S)-3-(7-(((1R)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
CAS:Formula:C23H28F2N6O4SPurity:98%Color and Shape:SolidMolecular weight:522.5680Ref: IN-DA00I57D
1g34.00€5g63.00€10g121.00€25g172.00€50g199.00€100g236.00€250g621.00€25mg27.00€100mg27.00€250mg30.00€Ticagrelor
CAS:<p>Ticagrelor (AR-C 126532XX), produced by AstraZeneca, is an inhibitor of platelet aggregation.</p>Formula:C23H28F2N6O4SPurity:98.08% - 99.77%Color and Shape:SolidMolecular weight:522.57Ticagrelor
CAS:Formula:C23H28F2N6O4SPurity:≥ 98.0%Color and Shape:White to off-white powderMolecular weight:522.57Ticagrelor
CAS:Formula:C23H28F2N6O4SPurity:>98.0%(HPLC)(qNMR)Color and Shape:White to Light yellow powder to crystalMolecular weight:522.57Ticagrelor Impurity 18
CAS:Formula:C7H9Cl2N3O2SColor and Shape:White To Off-White SolidMolecular weight:270.13Ticagrelor
CAS:Controlled Product<p>Stability Hygroscopic<br>Applications Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS).<br>References Matetzky, S., et al.: Circulation, 109, 3171 (2004), Bassand, J., et al.: Eur. Heart J., 28, 1598 (2007), Jakubowski, J., et al.: Cardiovasc. Drug Rev., 25, 357 (2007),<br></p>Formula:C23H28F2N6O4SColor and Shape:WhiteMolecular weight:522.57Ticagrelor
CAS:<p>Reversible P2Y12 receptor antagonist; ADP-induced platelet aggregation blocker</p>Formula:C23H28F2N6O4SPurity:Min. 95%Color and Shape:PowderMolecular weight:522.57 g/molTicagrelor - Bio-X ™
CAS:<p>Ticagrelor is a P2Y12 receptor antagonist that has been shown to reduce the risk of myocardial infarction. It inhibits the formation of thromboses. Ticagrelor binds to the adenosine diphosphate (ADP) site on the platelet P2Y receptor and prevents ADP from activating this receptor. It is used for the prevention of myocardial infarctions, strokes and cardiovascular disease.</p>Formula:C23H28F2N6O4SPurity:Min. 95%Color and Shape:PowderMolecular weight:522.57 g/molent-Ticagrelor-d7
CAS:Controlled ProductFormula:C23H21D7F2N6O4SColor and Shape:NeatMolecular weight:260.284
![(1S,2S,3R,5S)-3-(7-(((1R)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3h-[1,2,3]triazo…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FIN%2Fthumb%2FDA00I57D.jpg&w=3840&q=75)
